SAN JOSE, Calif., Jan. 16, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on using the body's immune system to fight cancer, today announced
that it will hold a conference call on January 24, 2019 at 1:30
p.m. Pacific / 4:30 p.m.
Eastern to discuss its plan for 2019, including the
commercialization path and timeline for Cchek™, its artificial
intelligence based cancer diagnostic test, and the clinical path of
its CAR-T based ovarian cancer therapeutic program.
"We are pleased with the advances made with both of our programs
to date, and are excited about where these programs are headed this
year. We believe 2019 will be a transformative year for Anixa
and we look forward to sharing our plans on this conference call,"
stated Dr. Amit Kumar, President and
CEO of Anixa Biosciences.
To access the call, please dial (866) 342-8591 five minutes
prior to the start time.
About Anixa Biosciences, Inc.
Anixa, a cancer-focused
biotechnology company, is harnessing the body's immune system in
the fight against cancer. Anixa is developing both
diagnostics and therapeutics to detect cancer early, when it is
most curable, and to treat those afflicted once diagnosed. It
is developing the Cchek™ platform, a series of inexpensive
non-invasive blood tests for the early detection of solid tumors,
which is based on the body's immune response to the presence of a
malignancy. It is also developing chimeric antigen receptor
T-cell (CAR-T) based immuno-therapy drugs which genetically
engineer a patient's own immune cells to fight cancer. Anixa
also continually examines emerging technologies in complementary or
related fields for further development and commercialization.
Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-hold-conference-call-to-discuss-outlook-for-2019-300779114.html
SOURCE Anixa Biosciences, Inc.